Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICAAC 2015: Data Help Theravance's Ongoing Vibativ Relaunch

This article was originally published in Scrip

Executive Summary

Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.


Related Content

Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts